Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study

Leuk Res. 2022 Feb:113:106788. doi: 10.1016/j.leukres.2022.106788. Epub 2022 Jan 11.

Authors

Nicholas L J Chornenki¹, Deborah M Siegal², Kiran Qamar³, Sabrina Woolgar³, Sumathy Rangarajan³, Sarah Karampatos³, Darryl P Leong⁴, Christopher M Hillis⁵

Affiliations

¹ Queen's University Internal Medicine Residency Program, Canada.
² Department of Medicine, The University of Ottawa, Canada.
³ Population Health Research Institute, Canada.
⁴ Population Health Research Institute, Canada; Department of Medicine, McMaster University, Canada.
⁵ Department of Oncology, McMaster University, Canada. Electronic address: hillisc@mcmaster.ca.

PMID: 35042128
DOI: 10.1016/j.leukres.2022.106788

No abstract available

Keywords: Frailty; MPNs; geriatric oncology; quality of life.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Canada / epidemiology
Female
Frailty / diagnosis
Frailty / drug therapy
Frailty / epidemiology*
Geriatric Assessment / methods
Geriatric Assessment / statistics & numerical data
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology*
Male
Middle Aged
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy
Myeloproliferative Disorders / epidemiology*
Polycythemia Vera / diagnosis
Polycythemia Vera / drug therapy
Polycythemia Vera / epidemiology*
Prevalence
Prospective Studies
Protein Kinase Inhibitors / therapeutic use
Surveys and Questionnaires
Thrombocythemia, Essential / diagnosis
Thrombocythemia, Essential / drug therapy
Thrombocythemia, Essential / epidemiology*

Substances

Protein Kinase Inhibitors